Non-Small Cell Lung Cancer (NSCLC) News Monitoring

BMS and BioNTech partner on solid tumour candidate in deal worth over $11bn

Bristol Myers Squibb (BMS) has entered into an agreement worth over $11bn to jointly develop and commercialise BioNTech’s investigational bispecific antibody across multiple solid tumour types. The candidate, BNT327, is currently being evaluated in …

Comparing Liposomal Bupivacaine and Ropivacaine in Serratus Anterior Plane Block for Thoracoscopic Lobectomy: A ...

Yang Zhang,1,* Wei Li,1,2,* Aiping Wei,1,* Shibiao Chen,1 Xiuhong Wang1 1Department of Anesthesiology, First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, 330006, People’s Republic of China; 2Department of …

Next Steps: Post-Frontline Therapies and Resistance in ALK+ NSCLC

Patritumab Deruxtecan BLA Withdrawn in Non-Small Cell Lung Cancer

The biologics license application (BLA) seeking accelerated approval for patritumab deruxtecan (HER3-DXd) for adult patients with previously treated, locally advanced/metastatic EGFR-mutated non-small cell lung cancer (NSCLC) in the U.S. has been …

Traws Pharma Announces Publication of Compelling Efficacy data in RDEB SCC Patients Treated with Legacy Oncology Drug ...

NEWTOWN, Pa., June 03, 2025 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (NASDAQ: TRAW) (“Traws Pharma”, “Traws” or “the Company”), a clinical-stage biopharmaceutical company developing novel therapies to target critical threats to human health from respiratory …

Patient-Reported Symptom Trends Could Help Guide Lung Cancer Trials and Care, Study Finds

Tracking how symptoms change over time in people with non-small cell lung cancer (NSCLC) may help predict survival and improve patient-centered care, according to new research out of the University of North Carolina. The study, published late last month in …

AstraZeneca & Daiichi Sankyo announce positive results from DESTINY-Breast09 phase III trial of Enhertu plus pertuzumab ...

Positive results from the DESTINY-Breast09 phase III trial showed Enhertu (trastuzumab deruxtecan) plus pertuzumab demonstrated a highly statistically significant and clinically meaningful improvement in progression-free survival (PFS) compared to a taxane …

Sacituzumab Tirumotecan Yields Superior Clinical Activity in EFGR+ NSCLC

The TROP2-directed antibody-drug conjugate (ADC) sacituzumab tirumotecan (sac-TMT; formerly SKB264/MK-2870) demonstrated statistically significant and clinically meaningful improvements in response rates and progression-free and overall survival (OS) …

Sevabertinib Exhibits Activity in Treatment-Naïve HER2-Mutant NSCLC

Sevabertinib (BAY 2927088) exhibited high and comparable objective response rates (ORRs) among patients with HER2-mutant non–small cell lung cancer (NSCLC) who received prior treatment excluding a HER2-targeted therapy, or who were treatment-naïve for …

HER3-DXd Does Not Yield Improved OS in EGFR-Mutated NSCLC

For patients with EGFR mutation–positive locally advanced or metastatic non–small cell lung cancer (NSCLC), patritumab deruxtecan (HER3-DXd) did not elicit improved overall survival (OS), according to results from the phase 3 HERTHENA-Lung02 trial ( …

Adagrasib/Pembrolizumab Yields Improved Survival in KRAS G12C-Mutated NSCLC

Adagrasib (Krazati) plus pembrolizumab (Keytruda) improved efficacy for patients with KRAS G12C-mutated non–small cell lung cancer (NSCLC), according to results from the phase 2 KRYSTAL-7 trial (NCT04613596) presented at the 2025 American Society of …

BMS Buys Into BioNTech Bispecific Antibody, Putting Up $1.5B to Collaborate in Multiple Cancers

BioNTech’s oncology strategy centers on a bispecific antibody that the company envisions as the backbone of many potential drug combinations for many types of cancer. Bristol Myer Squibb is buying into that strategy, paying $1.5 billion up front to partner …

Savolitinib Plus Osimertinib Hits PFS End Point in EGFR-Mutated, MET-Amplified NSCLC After Disease Progression With an ...

Savolitinib in combination with osimertinib (Tagrisso) demonstrated clinically meaningful efficacy improvements vs chemotherapy in patients with EGFR-mutated, MET-amplified advanced non–small cell lung cancer (NSCLC) who experienced disease progression …

Dr Spigel on Adjuvant Chemotherapy in Stage IA/IIA, Molecularly Higher-Risk NSCLC

"If you have a patient in front of you with nonsquamous, non–small cell lung cancer and early-stage disease, and you're already planning to give chemotherapy, [this molecular test is not necessary]. If you know—or the patient and their family know …

Verastem Announces Positive Data From Cancer Trial Conducted By Partner: Retail Turns Bullish

In a study conducted in China, GFH375, also known as VS-7375 in the U.S., showed an overall response rate of 52% in patients with pancreatic ductal adenocarcinoma and 42% in those with non-small cell lung cancer. Shares of Verastem Oncology (VSTM) dropped …

ASCO25: Focus V fails to show superiority over bevacizumab in first-line metastatic CRC

At the American Society of Clinical Oncology (ASCO) Annual Meeting, being held 31 May – 3 June, results from the randomised, Chinese multicenter Phase III ANCHOR clinical trial (NCT04854668) were presented. The non-inferiority trial evaluated the efficacy …

Immunotherapy before surgery boosts long term survival in lung cancer, trial shows

Results from a phase 3 clinical trial published in the New England Journal of Medicine, today (June 2nd) show that patients with lung cancer who received an immunotherapy drug, nivolumab, along with standard chemotherapy before surgery had improved long …

Evaluating Five-year Efficacy Outcomes in the EMPOWER-Lung 1 Study | Written Recap

Eric K. Singhi, M.D., is an assistant professor in the Department of Thoracic/Head and Neck Medical Oncology at The University of Texas MD Anderson Cancer Center in Houston, and Ben Creelan, M.D., is a medical oncologist and clinical researcher in the …

Assay Finds Patients Who Will Benefit From Adjuvant Chemotherapy in Early-Stage NSCLC

Biomarker testing for early-stage patients with nonsquamous non–small cell lung cancer (NSCLC) allowed investigators to find and treat those patients who would benefit from chemotherapy after surgery, even though traditional guidelines would not suggest it …

Fight Health Insurance Makes AI Billing Assistant Doughnut Free for Patients and Providers

Fight Health Insurance launches free AI billing chat for patients and providers, and adds customizable prior authorization letters for healthcare professionals SAN FRANCISCO, CA, UNITED STATES, June 3, 2025 /⁨EINPresswire.com⁩/ -- Conversational …

Antioch University Approved to Launch Graduate Nursing Programs Nationwide

Programs to Be Delivered Online, Expanding Access for Working Professionals YELLOW SPRINGS, OH, UNITED STATES, June 3, 2025 /⁨EINPresswire.com⁩/ -- Antioch University is proud to announce that the Higher Learning Commission’s Institutional …

The Boob Bus Partners With Cigna Healthcare to Expand Access to Breast Cancer Screenings Across Utah

Serving More Than 1900 Utah Women Since Its Launch, The Boob Bus Continues To Expand Access To Breast Cancer Screening With New Insurance Contract SALT LAKE CITY, UT, UNITED STATES, June 3, 2025 /⁨EINPresswire.com⁩/ -- In another step towards …

Melbourne Pharma Brings Expert Dermatological Compounding to Florida’s Sunshine State

Melbourne Pharma offers expert, custom dermatology compounding for Florida patients—led by pharmacist Mike Boehmer. MELBOURNE, FL, UNITED STATES, June 3, 2025 /⁨EINPresswire.com⁩/ -- With Florida’s abundant sunshine comes an increased need for …

Momentive Appoints Craig Borkowski as New Chief Executive Officer

NISKAYUNA, NY, UNITED STATES, June 3, 2025 /⁨EINPresswire.com⁩/ -- Momentive Performance Materials (Momentive), a global high-performance silicones and specialty solutions company, is pleased to announce the appointment of Craig Borkowski as Chief …

Testosterone Replacement Therapy Shows Mixed Effects on Heart Disease Risk, According to New Research Studies

Men with hypogonadal symptoms (low libido, muscle loss, erectile dysfunction, fatigue, etc.) show benefits from properly dosed and monitored TRT services NEW ORLEANS, LA, UNITED STATES, June 3, 2025 /⁨EINPresswire.com⁩/ -- Testosterone Replacement …

Longevity Leadership Conference Returns to Los Angeles: A Premier Gathering of Industry Innovators and Investors

Explore the intersection of science, medicine, investment, and business at the forefront of the longevity revolution. LOS ANGELES, CA, UNITED STATES, June 3, 2025 /⁨EINPresswire.com⁩/ -- Healthspan Productions, in partnership with Mission Matters …

Formaspace Announces Strategic Lab Chair Partnership with Cramer

Formaspace features specialized Cramer chairs—Fusion, Helix, and Loop—at NeoCon 2025, showroom #11-124. Built for labs, cleanrooms, and technical spaces. AUSTIN, TX, UNITED STATES, June 3, 2025 /⁨EINPresswire.com⁩/ -- Formaspace is announcing a …

Westfield Washington Schools & Bosma Enterprises Partner to Advance Student Vision Screenings with Good-Lite Technology

Westfield Schools partner with Bosma to enhance student vision screenings using Good-Lite’s LED Insta-Line Cabinet for accurate, efficient testing. WESTFIELD, IN, UNITED STATES, June 3, 2025 /⁨EINPresswire.com⁩/ -- Westfield Washington Schools ( …

Good-Lite Company. Now a preferred supplier for U.S. Veterans Association through GSA Schedule

Good-Lite Company is proud to announce its inclusion on the United States Veterans Association's list of preferred suppliers. ELGIN, IL, UNITED STATES, June 3, 2025 /⁨EINPresswire.com⁩/ -- Good-Lite Company., a leader in visual acuity …

Retinitis Pigmentosa Therapeutics Enter New Era as Gene-Agnostic & Intravitreal Therapies Redefine Competitive Landscape

Retinitis Pigmentosa therapies evolve beyond gene-specific fixes with gene-agnostic, intravitreal, and optogenetic advances reshaping the treatment landscape. AUSTIN, TX, UNITED STATES, June 3, 2025 /⁨EINPresswire.com⁩/ -- The treatment paradigm …

Next-Generation Therapies Reshape Gaucher’s Disease as Gene Therapy Advances Challenge Enzyme Replacement Dominance

Gene therapies challenge ERT dominance in Gaucher’s disease as new data reveals strategic insights, key players, and future treatment opportunities. AUSTIN, TX, UNITED STATES, June 3, 2025 /⁨EINPresswire.com⁩/ -- The Gaucher’s disease (GD) …

Blue Goat Cyber Sponsors LSI Asia 2025; CTO Trevor Slattery to Lead High-Impact MedTech Cybersecurity Panel

Blue Goat Cyber sponsors LSI Asia 2025 and leads a MedTech cybersecurity panel on avoiding regulatory and market pitfalls in APAC. SCOTTSDALE, AZ, UNITED STATES, June 3, 2025 /⁨EINPresswire.com⁩/ -- Blue Goat Cyber, a trusted authority in medical …

Global Hemp Fiber Market Set For 36.4% Growth, Reaching $71.96 Billion By 2029

The Business Research Company’s Hemp Fiber Global Market Report 2025 – Market Size, Trends, And Forecast 2025-2034 LONDON, GREATER LONDON, UNITED KINGDOM, June 3, 2025 /⁨EINPresswire.com⁩/ -- The hemp fiber market has seen unprecedented growth in …

Industrial Dispensing System And Equipment Market Forecast 2025-2034: Comprehensive Insights On Market Size, Growth

The Business Research Company’s Industrial Dispensing System And Equipment Global Market Report 2025 – Market Size, Trends, And Forecast 2025-2034 LONDON, GREATER LONDON, UNITED KINGDOM, June 3, 2025 /⁨EINPresswire.com⁩/ -- The industrial …

Figure Skater’s Legacy Becomes Maine Haven: Tessa’s House Opens 16 Beds for Women in Recovery

Trauma-informed, women-only facility honoring Tessa Lee McCue’s legacy and funded by a $1.1 million Maine Recovery Council grant. WASHINGTON, ME, UNITED STATES, June 3, 2025 /⁨EINPresswire.com⁩/ -- Addiction remains one of the most urgent women's …

Blue Goat Cyber Sponsors DeviceTalks Minnesota; Jordan John to Share FDA Cybersecurity Strategies

Blue Goat Cyber joins DeviceTalks Minnesota to showcase expert strategies for FDA-ready medical device cybersecurity and regulatory compliance. SCOTTSDALE, AZ, UNITED STATES, June 3, 2025 /⁨EINPresswire.com⁩/ -- Blue Goat Cyber, a leading …

SSOJet Launches Custom SSO Attributes Feature, Eliminating Enterprise User Management Complexity for B2B Applications

Breakthrough capability enables seamless mapping of enterprise customer data into application workflows, reducing custom integration work by up to 89% SAN FRANCISCO, CA, UNITED STATES, June 3, 2025 /⁨EINPresswire.com⁩/ -- SSOJet today announced …

Continuing Professional Development in Eye Care

Paradigm Medical Communications, LLC and the American Academy of Ophthalmology Announce the Continuation of Their Strategic Partnership in Eye Care PARADIGM MEDICAL COMMUNICATIONS, NY, UNITED STATES, June 3, 2025 /⁨EINPresswire.com⁩/ -- Paradigm …

Neurofibromatosis Type 1 (NF1) Drug Development Gains Momentum Amid Growing Need for Safer, More Effective Therapies

NF1 drug development accelerates with novel treatments aiming to surpass current MEK inhibitors in efficacy, safety, and patient-friendly delivery. AUSTIN, TX, UNITED STATES, June 3, 2025 /⁨EINPresswire.com⁩/ -- In the realm of rare genetic …